Date: 2011-12-01
Type of information: Grant
Company: Prosensa (The Netherlands)
Investors: Charley’s Fund (USA)
Amount: $1.5 million (€1.18 million)
Funding type: grant
Planned used: These funds will be used to support development of compounds for the skipping of exon 52 in patients with Duchenne Muscular Dystrophy (DMD).
Others: Prosensa has received financing of $1.5m for three years from the charitable organisation Charley’s Fund, to support development of compounds for the skipping of exon 52 in patients with Duchenne Muscular Dystrophy (DMD). Under the terms of the agreement, Prosensa will identify antisense oligonucleotides for the skipping of exon 52 in specific subpopulations of DMD patients. Prosensa will assess the safety and efficacy of the compounds in suitable preclinical models with the aim to move a selected candidate into clinical trials.
Therapeutic area: Rare diseases - Neuromuscular diseases